Drugs / EPREX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03223961 | Mar 2018 → Sep 2023 overdue | myelodysplastic syndrome | Groupe Francophone des Myelodysplasies | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPREX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03223961 ↗ |